TY - JOUR T1 - Mitochondrial DNA polymerase γ mutations: an ever expanding molecular and clinical spectrum JF - Journal of Medical Genetics JO - J Med Genet SP - 669 LP - 681 DO - 10.1136/jmedgenet-2011-100222 VL - 48 IS - 10 AU - Sha Tang AU - Jing Wang AU - Ni-Chung Lee AU - Margherita Milone AU - Michelle C Halberg AU - Eric S Schmitt AU - William J Craigen AU - Wei Zhang AU - Lee-Jun C Wong Y1 - 2011/10/01 UR - http://jmg.bmj.com/content/48/10/669.abstract N2 - Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial diseases in children and adults. This study sequenced the exons and flanking intronic regions of the POLG gene from 2697 unrelated patients with clinical presentations suggestive of POLG deficiency. Informative mutations have been identified in 136 unrelated individuals (5%), including 92 patients with two recessive pathogenic alleles and three patients harbouring a dominant mutation. Twenty-four novel recessive mutations and a novel possible dominant mutation, p.Y951N, were identified. All missense mutations occurred at evolutionarily conserved amino acids within functionally important regions identified by molecular modelling analyses. Oligonucleotide array comparative genomic hybridisation analyses performed on DNA samples from 81 patients with one mutant POLG allele identified a large intragenic deletion in only one patient, suggesting that large deletions in POLG are rare. The 92 patients with two mutant alleles exhibited a broad spectrum of disease. Almost all patients in all age groups had some degree of neuropathy. Seizures, hepatopathy, and lactic acidaemia were predominant in younger patients. By comparison, patients who developed symptoms in adulthood had a higher percentage of myopathy, sensory ataxia, and chronic progressive external ophthalmoplegia (CPEO)/ptosis. In conclusion, POLG mutations account for a broad clinical spectrum of mitochondrial disorders. Sequence analysis of the POLG gene should be considered as a part of routine screening for mitochondrial disorders, even in the absence of apparent mitochondrial DNA abnormalities. ER -